Naphcon-A

Active Ingredient(s): Naphazoline + Pheniramine
FDA Approved: * June 8, 1994
Pharm Company: * ALCON
Category: Allergies, Cough & Cold

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Naphcon-A Overview

Naphazoline/pheniramine, sold under the brand name Naphcon-A among others, is a combination eye drop used to help the symptoms of allergic conjunctivitis such as from hay fever.[2] It contains naphazoline and pheniramine.[2][1] It is used as an eye drop.[1] Use is not recommended for more than three days.[3] Side effects may include allergic reactions, eye pain, and dilated pupils.[2][4&...

Read more Naphcon-A Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Naphcon-A

Recent Naphcon-A Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Naphazoline + Pheniramine
  • Solution: 0.025% + 0.3%, 0.027% + 0.3%
  • Solution/drops: 0.025% + 0.3%, 0.02675% + 0.315%
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Naphcon-A: (4 results)

Sorted by National Drug Code
  • 0065-0085 Naphcon a Ophthalmic Solution/ Drops by Alcon Laboratories, Inc.
  • 50090-0185 Naphcon a Ophthalmic Solution/ Drops by A-s Medication Solutions
  • 52125-558 Naphcon a Ophthalmic Solution/ Drops by Remedyrepack Inc.
  • 52959-107 Naphcon a Ophthalmic Solution/ Drops by H.j. Harkins Company, Inc.

Drugs with one or more similar ingredients: (281 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 26 February 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA